Results 211 to 220 of about 83,254 (357)

Supplementary Table 1, Figures 1 - 2 from The Janus Kinases Inhibitor AZD1480 Attenuates Growth of Small Cell Lung Cancers <i>In Vitro</i> and <i>In Vivo</i>

, 2023
Jih‐Hsiang Lee, Kang‐Seo Park, Anna Teresa Alberobello, Bhaskar Kallakury, Meng‐Tzu Weng, Yisong Wang, Giuseppe Giaccone   +6 more
openalex   +2 more sources

Efficacy and Safety of Ritlecitinib in the Asian Subpopulation of the ALLEGRO‐2b/3 and ALLEGRO‐LT Clinical Studies for Alopecia Areata

The Journal of Dermatology, EarlyView.
ABSTRACT Ritlecitinib is an oral JAK3/TEC family kinase inhibitor approved for individuals aged ≥ 12 years with severe alopecia areata. Here we report interim efficacy and safety results with ritlecitinib up to Month 24 in the Asian subpopulation from the ALLEGRO phase 2b/3 and ALLEGRO‐LT studies.
Rie Ueki, Masato Mizuashi, Kazutoshi Harada, Xingqi Zhang, Wenyu Wu, Wen‐Hung Chung, Ohsang Kwon, Xin Luo, Victoria Basey, Robert Wolk, Nanzhi Shi, Kayo Fujita, Yimeng Shen, Tomohiro Hirose   +13 more
wiley   +1 more source

The Impact of Vehicle Occlusivity on Skin Delivery and Activity of a Janus Kinase Inhibitor: Comparison of Oil-Based Formulations. [PDF]

Pharmaceutics
Sarango-Granda P, Mohammadi-Meyabadi R, Braza AJ, Sosa L, Suñer-Carbó J, Mallandrich M, Calpena AC.   +6 more
europepmc   +1 more source

Response to Sood et al’s “Systemic Janus kinase inhibitor treatment for vitiligo: An evidence-based review” [PDF]

Caitlin A. Kearney, Carli D. Needle, Anna Brinks, Daniel Gutiérrez, Kristen I. Lo Sicco   +4 more
openalex   +1 more source

FDA-approved small-molecule kinase inhibitors [PDF]

, 2015
Clausen, Mads Hartvig, Nielsen, Thomas E., Wu, Peng   +2 more
core   +1 more source

Correction to: Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study. [PDF]

Calcif Tissue Int
Schulz N, Asendorf T, van Wijnen P, Wilhelmi T, Müller-Ladner U, Lange U, Klemm P.   +6 more
europepmc   +1 more source

Treating active rheumatoid arthritis with Janus kinase inhibitors [PDF]

The Lancet, 2017
Scott, David L, Stevenson, Matt D
openaire   +4 more sources

Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel, Peter Foley, Kathryn A. Gibson, Anita Townsend, Gabrielle Louise Reppen, William Romero Gallardo   +5 more
wiley   +1 more source

Incidental treatment of granulomatosis with polyangiitis with a Janus Kinase inhibitor in a patient undergoing alopecia treatment. [PDF]

JAAD Case Rep
Mendez D, Xiang L, Bergfeld W.
europepmc   +1 more source

LB1098 Association of sebaceous carcinoma and Janus kinase inhibitors: Case study and retrospective FAERS analysis [PDF]

Anupa Patel, L. Herbig, Paras P. Vakharia   +2 more
openalex   +1 more source